Antihypertensive drugs and the risk of congenital anomalies

Pharmacotherapy

Volumn 33, Issue 5, 2013, Pages 476-482

  Vasilakis Scaramozza, Catherine ^a   Aschengrau, Ann ^a   Cabral, Howard J ^a   Jick, Susan S ^b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antihypertensive; Congenital anomalies; Prevalence rates; Relative risk

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMINOPTERIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSULFAN; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETRETINATE; ISOTRETINOIN; METHOTREXATE; PHENYTOIN; THALIDOMIDE; TRIMETHADIONE; VALPROIC ACID; VASODILATOR AGENT;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; GENITAL MALFORMATION; HUMAN; INFANT; LIMB MALFORMATION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRENATAL DRUG EXPOSURE; PREVALENCE; PROGENY; RISK FACTOR; UNITED KINGDOM; URINARY TRACT MALFORMATION;

ABNORMALITIES, DRUG-INDUCED; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; GREAT BRITAIN; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREVALENCE; RISK;

EID: 84879559879     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1212     Document Type: Article

References (23)

1. Garovic V. Hypertension in pregnancy: diagnosis and treatment. Mayo Clin Proc 2000;75:1071-1076.
2. Friedman JM. ACE inhibitors and congenital anomalies. N Engl J Med 2006;354:2498-2500.
3. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-2451.
4. Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy - United States, Canada and Israel, 1987-1995. JAMA 1997;277:1193-1194.
5. Shotan A, Widerhorn J, Hurst A, Elkayarn U. Risks of angiotensin- converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994;95:451-456.
6. Yip SK, Leung TN, Fung HYM. Exposure to angiotensin-converting enzyme inhibitors during first trimester: is it safe to the fetus? Acta Obstet Gynecol Scand 1998;77:570-571.
7. Rigó J Jr, Adám Z. Angiotensin-converting enzyme inhibitors in pregnancy: a new aspect of indication [letter]. Acta Obstet Gynecol Scand 1999;78(2):169.
8. Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 2003;12:633-646.
9. Diav-Citrin O, Shechtman S, Halberstadt Y, et al. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol 2011;31(4):540-545.
10. Henriksen T. Hypertension in pregnancy: use of antihypertensive drugs. Acta Obstet Gynecol Scand 1997;76(2):96-106.
11. Magee LA, Schick B, Donnenfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol 1996;174 (3):823-828.
12. Yoshida T, Tadegawa Y, Miyago M, Hasegawa Y. Hyperphalangism induced by Ca-Blockers in rat fetuses. Teratology 1989;40:668-669.
13. Caton AR, Bell EM, Druschel CM, et al. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension. 2009; 54: 63-70.
14. Butters L, Kennedy S, Rubia PC. Atenolol in essential hypertension during pregnancy. BMJ 1990;301:587-589.
15. Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med 1996;335:257-265.
16. Hünseler C, Paneitz A, Friedrich D, et al. Angiotensin II receptor blocker induced fetopathy: 7 cases. Klin Padiatr 2011;223(1):10-14.
17. Jick H, Jick S, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-768.
18. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992;1:347-349.
19. García Rodríguez LA, Pérez Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol. 1998; 45:419-425
20. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-689.
21. Jick SS, Terris BZ. Anticonvulsants and congenital malformations. Pharmacotherapy 1997;17:561-564.
22. Jick SS. Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 1999;19(2):221-222.
23. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA; National Birth Defects Prevention Study. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol. 2003;67(3):193-201.